---
title: "Praxis Precision Medicines, Inc. Stock 12‑Month Price Target Raised to $620.95, Implies 95% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295155264.md"
description: "Analysts have raised the 12-month price target for Praxis Precision Medicines, Inc. to $620.95, implying a 95% upside from the August 5 closing price. The average target increased from $604.83, with forecasts ranging between $188 and $1,201. The consensus rating remains 'Buy' among 19 covering analysts."
datetime: "2026-08-06T23:20:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295155264.md)
  - [en](https://longbridge.com/en/news/295155264.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295155264.md)
---

# Praxis Precision Medicines, Inc. Stock 12‑Month Price Target Raised to $620.95, Implies 95% Upside

-   According to estimates from 19 analysts, Praxis Precision Medicines, Inc. stock's average price target has risen from $604.83 to $620.95, with forecasts ranging from $188 to $1201 per share
-   Based on the Aug. 5 closing price, the updated target implies approximately 95% potential upside
-   Consensus rating remains at “Buy” across 19 covering analysts, with 17 Buys, 1 Holds and 1 Sells

Explore more price target data and ratings for Praxis Precision Medicines, Inc. on the , and track all previous and future analyst recommendations for Praxis Precision Medicines, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [PRAX.US](https://longbridge.com/en/quote/PRAX.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Praxis Q2 2026 results: $1.4 billion liquidity supports runway into 2028](https://longbridge.com/en/news/295110125.md)
- [Praxis Precision Q2 net loss widens on higher expenses](https://longbridge.com/en/news/295106132.md)
- [These 5 warnings hint that one of the longest winning streaks in stock market history is coming to an end](https://longbridge.com/en/news/295128734.md)
- [Praxis Precision Medicines grants 7,318 RSUs to 29 new employees under 2024 inducement plan](https://longbridge.com/en/news/294862721.md)
- [Praxis Precision Medicines posts investor deck highlighting late-stage CNS pipeline, upcoming PDUFA dates](https://longbridge.com/en/news/295108601.md)